AGM/EGMSep 24, 2026, 04:02 PM
Legend Biotech Holds 2026 AGM; Approves Auditor, Director Elections, and Share Plan Amendment
AI Summary
Legend Biotech Corporation held its 2026 Annual General Meeting of Shareholders on September 24, 2026. Key outcomes included the reception of audited financial statements for the fiscal year ended December 31, 2025, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Additionally, four directors were re-elected, and the company's 2020 Restricted Shares Plan was amended to increase the number of shares reserved for issuance by 19,100,000. Approximately 84.9% of the company's outstanding shares were present at the meeting.
Key Highlights
- Legend Biotech shareholders ratified the appointment of Ernst & Young LLP as independent auditor for fiscal year 2026.
- Four Class III directors, including Mr. Robin Meng and Dr. Peter Salovey, were re-elected for three-year terms.
- Shareholders approved the amendment and restatement of the 2020 Restricted Shares Plan, increasing share reserve by 19,100,000.
- Audited consolidated financial statements for the fiscal year ended December 31, 2025, were received.
- Approximately 84.9% of outstanding shares were represented at the AGM.
Price Impact
More from LEGN